UQ-CSL V451

**UQ-CSL V451** was an investigational, MF59-adjuvanted recombinant protein-subunit COVID-19 vaccine developed by The University of Queensland and CSL. It contained a mammalian-cell-produced SARS-CoV-2 spike glycoprotein held in its prefusion conformation with UQ's molecular clamp technology, which incorporated HIV-1 glycoprotein 41-derived sequences. Administered intramuscularly, the vaccine was designed to induce anti-spike neutralising antibodies and cellular immune responses to prevent COVID-19. Phase 1 testing showed a favourable safety profile and robust immune responses, but the program was not advanced to Phase 2/3 because vaccine-induced antibodies to the gp41-derived clamp interfered with certain HIV diagnostic assays, producing false-positive test results without causing HIV infection. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33887208/))

Other names

SARS-CoV-2 SclampSARS-CoV2 SclampSARS-CoV 2 Sclampspike glycoprotein-clamp vaccine